U.S. FDA compels government officials to review antibody tests data

Date: 2020-04-15   Author: Saipriya Iyer  Category: #news

U.S. FDA compels government officials to review antibody tests data

The U.S. FDA (Food and Drug Administration) has reportedly announced that the government scientists will review lab tests data of patients that have antibodies to coronavirus.

In mid-March, the FDA loosened its regulatory standards on companies that offer antibody tests without the need to submit the evidence of their diagnostic testing. This has been carried out to achieve rapid testing capacity, which is critical in response to the COVID-19 pandemic. However, this has reportedly led to the increased prevalence of low-quality tests in the market.

The antibody test is extremely crucial for the government officials while making decisions regarding the reopening of the country. It will help identify people who are potentially immune to the disease. However, poor quality of the tests will lead to more fatal risks by wrongly identifying people as being immune to the disease when they do not have the antibodies.

Stephen Hahn, FDA Commissioner, has reportedly informed Scott Becker and other members of the Association of Public Health Laboratories that the NCI (National Cancer Institute) would start reviewing various tests in the market to check whether they obtain accurate results.

Mr. Becker stated that the members of the Association of Public Health Laboratories, which represents up to 125 county, state, & municipal public health labs in the United States, would have preferred the U.S. FDA changing the rules to make it mandatory for the testing companies to provide the results or data and prove the effectiveness of the test.

The evaluation, which is expected to be completed soon, will assure the American population regarding the quality of these antibody tests. Nearly 90 companies have reportedly been selling the antibody tests. However, it remains unclear how many tests will be reviewed and evaluated by the NCI to check its efficacy.

The FDA has declined to respond to queries regarding the statement.

Source credit:

https://edition.cnn.com/2020/04/14/health/fda-reverses-antibody-tests/index.html



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

India-based Kaizen AI set to influence the $1.36 trillion GCC realty sector

Author: Pankaj Singh

Kaizen AI, a prominent technology firm that uses AI to revolutionize large-scale building projects, is entering the lucrative GCC real estate sector, where the value of planned and under-construction projects is projec...


Microsoft expands partnership with Oracle to Deliver Oracle Database Services

Author: Pankaj Singh

Microsoft Corp. and Oracle Corp. have reportedly announced the availability of Oracle Database@Azure, which provides direct access to the Oracle database services operating on Oracle Cloud Infrastructure ...


Reliance Industries and NVIDIA join hands to advance AI in India

Author: Pankaj Singh

Indian billionaire Mukesh Ambani-owned Reliance Industries Ltd. has reportedly announced a partnership with U.S.-based chipmaker NVIDIA for advancing AI in India.

Apparently, Indi...